- Trio wins chemistry Nobel for protein design, prediction
- Braving war: Lebanon's 'badass' airline defies odds
- US weighs Google breakup in landmark trial
- Chinese stocks tumble on stimulus upset, Asia tracks Wall St higher
- 7-Eleven owner confirms new takeover offer from Couche-Tard
- A US climate scientist sees hurricane Helene's devastation firsthand
- Can carbon credits help close coal plants?
- Boeing suspends negotiations with striking workers
- 7-Eleven owner's shares spike on report of new buyout offer
- Your 'local everything': what 7-Eleven buyout battle means for Japan
- AI-aided research, new materials eyed for Nobel Chemistry Prize
- The US economy is solid: Why are voters gloomy?
- Scientists sound AI alarm after winning physics Nobel
- Nobel-winning physicist 'unnerved' by AI technology he helped create
- Trump secretly sent Covid tests to Putin: Bob Woodward book
- Neural networks, machine learning? Nobel-winning AI science explained
- Boeing delivers 27 MAX jets in September despite strike
- Stock markets diverge as Hong Kong sinks, oil prices fall
- US trade gap narrowest in five months as imports slip
- Stay and 'you are going to die': Florida braces for next hurricane
- Geoffrey Hinton, soft-spoken godfather of AI
- Duo wins Physics Nobel for 'foundational' AI breakthroughs
- German 'Maddie' suspect could be free in 2025 after cleared of separate sex crimes
- China slaps provisional tariffs on EU brandy imports
- Duo wins Physics Nobel for key breakthroughs in AI
- German 'Maddie' suspect could be free soon after cleared of separate sex crimes
- China says to take anti-dumping measures against EU brandy imports
- China stocks rally fizzles on stimulus worries amid Asia retreat
- China stocks rally peters out on stimulus worries amid Asia retreat
- Taiwan's Foxconn says building world's largest 'superchip' plant
- Nobel literature jury may go for non-Western writer
- From Bolivia to Indonesia, deforestation continues apace
- China holds off on fresh stimulus but 'confident' will hit growth target
- German suspect in 'Maddie' case faces verdict in sex crimes trial
- Top economic official 'confident' China will hit 2024 growth target
- COP29 fight looms over climate funds for developing world
- Shanghai stocks soar to extend stimulus rally amid Asia-wide drop
- Will Tesla's robotaxi reveal live up to hype?
- 'Invisibility' and quantum computing tipped for physics Nobel
- Oil prices extend gains on Mideast tensions, Wall Street falls
- 'Dark day': Victims mourned around the globe on Oct. 7 anniversary
- Mission to probe smashed asteroid launches despite hurricane
- Oil prices extend gains on Mideast tensions, Wall Street slips
- Europe's asteroid mission Hera launches despite hurricane
- Oil prices extend gains on Mideast tensions, Wall Street retreats
- What is microRNA? Nobel-winning discovery explained
- Weather may delay launch of mission to study deflected asteroid
- China to flesh out economic stimulus plans after bumper rally
- Asian markets track Wall St rally on US jobs data
- World marks anniversary of Oct. 7 attack on Israel
Germany's BioNTech plans UK trial of mRNA cancer therapy
German pharmaceutical company BioNTech, which developed a trailblazing Covid-19 vaccine, will trial a cancer treatment in Britain using the same mRNA technology, the company said on Friday.
Up to 10,000 people will receive the immunotherapy tailored to individual tumours by the end of 2030, either in trials or as an approved treatment, BioNTech said in a statement.
The project is part of a new agreement with the British government focused on "cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UK", the company said.
BioNTech will also open a new research and development centre with around 70 staff in Cambridge, as well as setting up a regional headquarters in London.
"Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years," said Ugur Sahin, CEO and co-founder of BioNTech.
The UK "successfully delivered Covid-19 vaccines so quickly", he said, demonstrating "that drug development can be accelerated without cutting corners if everyone works seamlessly together towards the same goal".
The messenger RNA method made its debut with the Pfizer/BioNTech coronavirus vaccine, which was the first jab against Covid to be approved in the West in late 2020.
Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases.
They also take less time to develop than traditional vaccines.
BioNTech's Covid-19 shot was developed and approved by regulators in less than a year.
BioNTech is also working on mRNA-based vaccines against malaria, influenza and shingles.
The company has been developing mRNA-based cancer therapies since it was founded in 2008 and they have been trialled on several hundred people so far.
P.Kolisnyk--CPN